1769 related articles for article (PubMed ID: 26121236)
1. Matrix metalloproteinases as therapeutic targets for idiopathic pulmonary fibrosis.
Craig VJ; Zhang L; Hagood JS; Owen CA
Am J Respir Cell Mol Biol; 2015 Nov; 53(5):585-600. PubMed ID: 26121236
[TBL] [Abstract][Full Text] [Related]
2. Matrix metalloproteinase: An upcoming therapeutic approach for idiopathic pulmonary fibrosis.
Mahalanobish S; Saha S; Dutta S; Sil PC
Pharmacol Res; 2020 Feb; 152():104591. PubMed ID: 31837390
[TBL] [Abstract][Full Text] [Related]
3. Role of matrix metalloproteinases in the pathogenesis of idiopathic pulmonary fibrosis.
Pardo A; Cabrera S; Maldonado M; Selman M
Respir Res; 2016 Mar; 17():23. PubMed ID: 26944412
[TBL] [Abstract][Full Text] [Related]
4. MMP expression and abnormal lung permeability are important determinants of outcome in IPF.
McKeown S; Richter AG; O'Kane C; McAuley DF; Thickett DR
Eur Respir J; 2009 Jan; 33(1):77-84. PubMed ID: 18829682
[TBL] [Abstract][Full Text] [Related]
5. Circulating matrix metalloproteinases and tissue metalloproteinase inhibitors in patients with idiopathic pulmonary fibrosis in the multicenter IPF-PRO Registry cohort.
Todd JL; Vinisko R; Liu Y; Neely ML; Overton R; Flaherty KR; Noth I; Newby LK; Lasky JA; Olman MA; Hesslinger C; Leonard TB; Palmer SM; Belperio JA;
BMC Pulm Med; 2020 Mar; 20(1):64. PubMed ID: 32171287
[TBL] [Abstract][Full Text] [Related]
6. Pivotal role of matrix metalloproteinase 13 in extracellular matrix turnover in idiopathic pulmonary fibrosis.
Nkyimbeng T; Ruppert C; Shiomi T; Dahal B; Lang G; Seeger W; Okada Y; D'Armiento J; Günther A
PLoS One; 2013; 8(9):e73279. PubMed ID: 24023851
[TBL] [Abstract][Full Text] [Related]
7. Upregulation and Nuclear Location of MMP28 in Alveolar Epithelium of Idiopathic Pulmonary Fibrosis.
Maldonado M; Salgado-Aguayo A; Herrera I; Cabrera S; Ortíz-Quintero B; Staab-Weijnitz CA; Eickelberg O; Ramírez R; Manicone AM; Selman M; Pardo A
Am J Respir Cell Mol Biol; 2018 Jul; 59(1):77-86. PubMed ID: 29373068
[TBL] [Abstract][Full Text] [Related]
8. The Rho kinases: critical mediators of multiple profibrotic processes and rational targets for new therapies for pulmonary fibrosis.
Knipe RS; Tager AM; Liao JK
Pharmacol Rev; 2015; 67(1):103-17. PubMed ID: 25395505
[TBL] [Abstract][Full Text] [Related]
9. Matrix metalloproteinase-19 is a key regulator of lung fibrosis in mice and humans.
Yu G; Kovkarova-Naumovski E; Jara P; Parwani A; Kass D; Ruiz V; Lopez-Otín C; Rosas IO; Gibson KF; Cabrera S; Ramírez R; Yousem SA; Richards TJ; Chensny LJ; Selman M; Kaminski N; Pardo A
Am J Respir Crit Care Med; 2012 Oct; 186(8):752-62. PubMed ID: 22859522
[TBL] [Abstract][Full Text] [Related]
10. Pleiotropic effect of the proton pump inhibitor esomeprazole leading to suppression of lung inflammation and fibrosis.
Ghebremariam YT; Cooke JP; Gerhart W; Griego C; Brower JB; Doyle-Eisele M; Moeller BC; Zhou Q; Ho L; de Andrade J; Raghu G; Peterson L; Rivera A; Rosen GD
J Transl Med; 2015 Aug; 13():249. PubMed ID: 26231702
[TBL] [Abstract][Full Text] [Related]
11. Matrix metalloproteinases inhibitors in idiopathic pulmonary fibrosis: Medicinal chemistry perspectives.
Yue L; Shi Y; Su X; Ouyang L; Wang G; Ye T
Eur J Med Chem; 2021 Nov; 224():113714. PubMed ID: 34315043
[TBL] [Abstract][Full Text] [Related]
12. Production and activation of matrix metalloproteinase 7 (matrilysin 1) in the lungs of patients with idiopathic pulmonary fibrosis.
Fujishima S; Shiomi T; Yamashita S; Yogo Y; Nakano Y; Inoue T; Nakamura M; Tasaka S; Hasegawa N; Aikawa N; Ishizaka A; Okada Y
Arch Pathol Lab Med; 2010 Aug; 134(8):1136-42. PubMed ID: 20670133
[TBL] [Abstract][Full Text] [Related]
13. Matrix metalloproteinase-10: a novel biomarker for idiopathic pulmonary fibrosis.
Sokai A; Handa T; Tanizawa K; Oga T; Uno K; Tsuruyama T; Kubo T; Ikezoe K; Nakatsuka Y; Tanimura K; Muro S; Hirai T; Nagai S; Chin K; Mishima M
Respir Res; 2015 Sep; 16():120. PubMed ID: 26415518
[TBL] [Abstract][Full Text] [Related]
14. Matrix Metalloproteinases Retain Soluble FasL-mediated Resistance to Cell Death in Fibrotic-Lung Myofibroblasts.
Nareznoi D; Konikov-Rozenman J; Petukhov D; Breuer R; Wallach-Dayan SB
Cells; 2020 Feb; 9(2):. PubMed ID: 32053892
[TBL] [Abstract][Full Text] [Related]
15. Loss of MT1-MMP in Alveolar Epithelial Cells Exacerbates Pulmonary Fibrosis.
Placido L; Romero Y; Maldonado M; Toscano-Marquez F; Ramírez R; Calyeca J; Mora AL; Selman M; Pardo A
Int J Mol Sci; 2021 Mar; 22(6):. PubMed ID: 33805743
[TBL] [Abstract][Full Text] [Related]
16. Endothelial cell-derived MMP19 promotes pulmonary fibrosis by inducing E(nd)MT and monocyte infiltration.
Zhao W; Wang L; Yang J; Chen X; Guo X; Xu K; Wang N; Zhao W; Xia C; Lian H; Rosas I; Yu G
Cell Commun Signal; 2023 Mar; 21(1):56. PubMed ID: 36915092
[TBL] [Abstract][Full Text] [Related]
17. Tumor necrosis factor-α accelerates the resolution of established pulmonary fibrosis in mice by targeting profibrotic lung macrophages.
Redente EF; Keith RC; Janssen W; Henson PM; Ortiz LA; Downey GP; Bratton DL; Riches DW
Am J Respir Cell Mol Biol; 2014 Apr; 50(4):825-37. PubMed ID: 24325577
[TBL] [Abstract][Full Text] [Related]
18. Elevated gelatinase activity in pulmonary alveolar proteinosis: role of macrophage-colony stimulating factor.
Bonfield TL; Swaisgood CM; Barna BP; Farver CF; Kavuru MS; Thomassen MJ
J Leukoc Biol; 2006 Jan; 79(1):133-9. PubMed ID: 16275889
[TBL] [Abstract][Full Text] [Related]
19. Idiopathic pulmonary fibrosis: Epithelial-mesenchymal interactions and emerging therapeutic targets.
Hewlett JC; Kropski JA; Blackwell TS
Matrix Biol; 2018 Oct; 71-72():112-127. PubMed ID: 29625182
[TBL] [Abstract][Full Text] [Related]
20. MMP28 in Idiopathic Pulmonary Fibrosis: Beyond the Extracellular Matrix.
Atamas SP
Am J Respir Cell Mol Biol; 2018 Jul; 59(1):5-6. PubMed ID: 29957054
[No Abstract] [Full Text] [Related]
[Next] [New Search]
